Business Context and Reporting Period
This Form 8-K is filed by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc.) on March 10, 2016. The report announces the financial results for the fourth quarter and the full year ended December 31, 2015. The detailed financial data is contained in a press release furnished as Exhibit 99.1 and incorporated by reference.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the attached press release (Exhibit 99.1), which is not included in the provided source text.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the text provided. It serves as a notification that the results for the period ended December 31, 2015, have been issued.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished pursuant to Item 2.02 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. The company undertakes no duty or obligation to publicly update or revise the information so furnished, except as required by law. No specific guidance, outlook, or risk factors are detailed in the text of this 8-K.
Investor Verification Checklist
- Verify the correct registrant name is Cara Therapeutics, Inc., as the input metadata incorrectly listed "Tvardi Therapeutics, Inc."
- Review Exhibit 99.1 (the March 10, 2016 press release) for actual financial figures, as they are not present in the 8-K text.
- Confirm the reporting period covers the fourth quarter and full year ended December 31, 2015.
- Note that the financial data in the press release is not deemed "filed" under Section 18 of the Exchange Act.